Overview

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.

Phase:

PHASE2

Details

Lead Sponsor:

Sirtsei Pharmaceuticals, Inc.

Collaborator:

Rho, Inc.